checkAd
    Ultragenyx Pharmaceutical Aktie
    37,40
     
    EUR
    +1,08 %
    +0,40 EUR
    Letzter Kurs 24.05.24 Tradegate
    37,20
     
    EUR
    162 STK
    Geldkurs 24.05.24
    37,40
     
    EUR
    160 STK
    Briefkurs 24.05.24
    ISIN: US90400D1081 · WKN: A1XCY0 · SYM: UP0 · USA

    Neueste Nachrichten

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    17.05.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
    07.05.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
    02.05.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
    30.04.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
    30.04.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
    25.04.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    19.04.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
    15.04.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
    12.04.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
    12.04.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    22.03.24 · globenewswire · Ultragenyx Pharmaceutical
    Ultragenyx to Participate at Investor Conferences in March
    27.02.24 · globenewswire · Ultragenyx Pharmaceutical